BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 36255589)

  • 1. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options.
    Brazel D; Kroening G; Nagasaka M
    BioDrugs; 2022 Nov; 36(6):717-729. PubMed ID: 36255589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of amivantamab for the treatment of non-small cell lung cancer.
    Brazel D; Nagasaka M
    Respir Res; 2023 Oct; 24(1):256. PubMed ID: 37880647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
    Hernandez L; Young M
    J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869
    [No Abstract]   [Full Text] [Related]  

  • 4. [Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].
    Yang X; Zhao J
    Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):337-350. PubMed ID: 35599009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies.
    Bai Q; Wang J; Zhou X
    Cancer Treat Rev; 2023 Nov; 120():102605. PubMed ID: 37703723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.
    Chouaid C; Bosquet L; Girard N; Kron A; Scheffler M; Griesinger F; Sebastian M; Trigo J; Viteri S; Knott C; Rodrigues B; Rahhali N; Cabrieto J; Diels J; Perualila NJ; Schioppa CA; Sermon J; Toueg R; Erdmann N; Mielke J; Nematian-Samani M; Martin-Fernandez C; Pfaira I; Li T; Mahadevia P; Wolf J
    Adv Ther; 2023 Mar; 40(3):1187-1203. PubMed ID: 36652175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.
    Russell MC; Garelli AM; Reeves DJ
    Ann Pharmacother; 2023 Feb; 57(2):198-206. PubMed ID: 35652704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations.
    David GM; Maria Del Pilar BC; Cristina MR
    J Oncol Pharm Pract; 2023 Jun; 29(4):934-943. PubMed ID: 36916182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia.
    Okahisa M; Udagawa H; Matsumoto S; Kato T; Yokouchi H; Furuya N; Kanemaru R; Toyozawa R; Nishiyama A; Ohashi K; Miyamoto S; Nishino K; Nakamura A; Iwama E; Niho S; Oi H; Sakai T; Shibata Y; Izumi H; Sugiyama E; Nosaki K; Umemura S; Zenke Y; Yoh K; Kah Mun Low G; Zhuo J; Goto K
    Lung Cancer; 2024 May; 191():107798. PubMed ID: 38669727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive progress for non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: A novel targeted therapy option.
    Zhang W; Dong X
    J Oncol Pharm Pract; 2021 Dec; 27(8):2007-2009. PubMed ID: 34569378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
    Wu JY; Yu CJ; Shih JY
    Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-small cell lung cancer with
    Kwon CS; Lin HM; Crossland V; Churchill EN; Curran E; Forsythe A; Tomaras D; Ou SI
    Curr Med Res Opin; 2022 Aug; 38(8):1341-1350. PubMed ID: 35621011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives.
    Boch T; Köhler J; Janning M; Loges S
    Cancer Biol Med; 2022 Dec; 19(11):1543-64. PubMed ID: 36476337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
    Park K; Haura EB; Leighl NB; Mitchell P; Shu CA; Girard N; Viteri S; Han JY; Kim SW; Lee CK; Sabari JK; Spira AI; Yang TY; Kim DW; Lee KH; Sanborn RE; Trigo J; Goto K; Lee JS; Yang JC; Govindan R; Bauml JM; Garrido P; Krebs MG; Reckamp KL; Xie J; Curtin JC; Haddish-Berhane N; Roshak A; Millington D; Lorenzini P; Thayu M; Knoblauch RE; Cho BC
    J Clin Oncol; 2021 Oct; 39(30):3391-3402. PubMed ID: 34339292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of
    Yun J; Lee SH; Kim SY; Jeong SY; Kim JH; Pyo KH; Park CW; Heo SG; Yun MR; Lim S; Lim SM; Hong MH; Kim HR; Thayu M; Curtin JC; Knoblauch RE; Lorenzi MV; Roshak A; Cho BC
    Cancer Discov; 2020 Aug; 10(8):1194-1209. PubMed ID: 32414908
    [No Abstract]   [Full Text] [Related]  

  • 16. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
    Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer.
    Seo D; Lim JH
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence, Treatment Patterns, and Outcomes of Individuals with
    O'Sullivan DE; Jarada TN; Yusuf A; Hu LXY; Gogna P; Brenner DR; Abbie E; Rose JB; Eaton K; Elia-Pacitti J; Ewara EM; Pabani A; Cheung WY; Boyne DJ
    Curr Oncol; 2022 Sep; 29(10):7198-7208. PubMed ID: 36290844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Hu M; Zhong C; Wang J; Chen J; Zhou T
    Front Immunol; 2024; 15():1399975. PubMed ID: 38774882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
    Robichaux JP; Elamin YY; Tan Z; Carter BW; Zhang S; Liu S; Li S; Chen T; Poteete A; Estrada-Bernal A; Le AT; Truini A; Nilsson MB; Sun H; Roarty E; Goldberg SB; Brahmer JR; Altan M; Lu C; Papadimitrakopoulou V; Politi K; Doebele RC; Wong KK; Heymach JV
    Nat Med; 2018 May; 24(5):638-646. PubMed ID: 29686424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.